CHR Verviers

Verviers 20 trials 10 recruiting

20 Registered trials

10 Currently recruiting

Organisation

CHR Verviers

Location

Verviers, Belgium

Identifier

ORG-100042382

Address

Rue Du Parc 29, 4800, Belgium

Departments

Departement of Hematology
Department of Onco -Hematology
Hematology
Medical Oncology
Oco-hematologie
Onco-haematology
Onco-hematology
Oncologie
Oncology
Oncology & Hematology
Oncology Department
Radiotherapy-Oncology

Clinical trials at this site (20)

Search interface

Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5 2026-04-23
Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Metastatic renal cell carcinoma (mRCC) 5 2024-04-12
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting

2022-502703-30-00 neuroendocrine tumours 6 2023-06-28
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial t… Recruiting

2022-502373-42-00 Oligorecurrent hormone-sensitive prostate cancer patien 5 2022-04-25
A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma Recruiting

2024-516181-11-00 RELAPSE/REFRACTORY B-CELL LYMPHOMA. 4 2021-06-10
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Ended

2022-502046-28-00 HER2-Positive, PIK3CA Mutated, Locally Advanced or Meta 5 2023-12-22
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended

2023-507890-17-00 Anemia associated with myeloproliferative neoplasm (MPN 5 2021-02-22
KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA… Ended

2024-513252-15-00 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL 4 2021-01-28
A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Ended

2022-502798-40-00 Patients with resected colon carcinoma 5 2017-07-31
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended

2024-516198-61-00 Patients with high risk of relapse, ER+ and HER2- prima 5 2013-06-05
Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended

2024-516996-34-00 oestrogen-receptor (ER)-positive HER2-negative breast c 5 2012-04-12
Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc… Ended

2024-513167-68-00 endometrial cancer 5 2017-11-29
A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref… Ended

2023-509472-42-00 Relapsed and/or Refractory Multiple Myeloma 5